Fig. 5.

Overall and progression-free survival of patients treated with neoadjuvant chemotherapy and interval cytoreductive surgery (NAC) or primary cytoreductive surgery and adjuvant chemotherapy (PCS) stratified by sensitivity to platinum-based chemotherapy. All patients with first-line platinum-resistance had a worse (A) overall and (B) progression-free survival (p < 0.001). Treatment with neoadjuvant chemotherapy had no effect on the survival of the platinum-resistant patients. However, within the platinum-sensitive group, patients treated with neoadjuvant chemotherapy had worse overall and progression-free survival (p < 0.001). All statistics were calculated with a log-rank (Mantel–Cox) test. Bonferroni corrections were applied for all multiple comparisons. N/S = nonsignificant.